We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

7 hedge funds and large institutions have $845K invested in Alexion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 693 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

99% less funds holding

Funds holding: 707 → 7 (-700)

100% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 693

100% less funds holding in top 10

Funds holding in top 10: 77 → 0 (-77)

100% less capital invested

Capital invested by funds: $38.8B → $845K (-$38.8B)

Holders
7
Holders Change
-700
Holders Change %
-99.01%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
-77
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
693
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NICM
Neo Ivy Capital Management
New York
+$475K
2
TAIM
TD Ameritrade Investment Management
Nebraska
+$131K
3
RG
Retirement Group
California
+$9.37K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$3.74B
2
BlackRock
BlackRock
New York
-$3.21B
3
State Street
State Street
Massachusetts
-$1.84B
4
FCM
Farallon Capital Management
California
-$1.42B
5
HI
HBK Investments
Texas
-$1.21B
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
– -$193M -1,052,026 Closed
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$192M -1,045,496 Closed
Hudson Bay Capital Management
53
Hudson Bay Capital Management
Connecticut
– -$188M -1,020,985 Closed
Arrowstreet Capital
54
Arrowstreet Capital
Massachusetts
– -$184M -1,002,319 Closed
RL
55
Ruffer LLP
United Kingdom
– -$183M -998,268 Closed
UBS AM
56
UBS AM
Illinois
– -$183M -996,173 Closed
California Public Employees Retirement System
57
California Public Employees Retirement System
California
– -$174M -949,278 Closed
TAL
58
TIG Advisors LLC
New York
– -$173M -939,232 Closed
Tudor Investment Corp
59
Tudor Investment Corp
Connecticut
– -$167M -907,855 Closed
Wells Fargo
60
Wells Fargo
California
– -$166M -904,290 Closed
PHS
61
PFM Health Sciences
California
– -$166M -901,441 Closed
Swiss National Bank
62
Swiss National Bank
Switzerland
– -$166M -900,881 Closed
MAM
63
Melqart Asset Management
United Kingdom
– -$163M -885,384 Closed
Capstone Investment Advisors
64
Capstone Investment Advisors
New York
– -$160M -868,549 Closed
Bank of Montreal
65
Bank of Montreal
Ontario, Canada
– -$155M -839,239 Closed
Royal Bank of Canada
66
Royal Bank of Canada
Ontario, Canada
– -$153M -831,958 Closed
Goldman Sachs
67
Goldman Sachs
New York
– -$144M -781,412 Closed
PPA
68
Parametric Portfolio Associates
Washington
– -$143M -776,990 Closed
Balyasny Asset Management
69
Balyasny Asset Management
Illinois
– -$142M -771,620 Closed
SCM
70
Segantii Capital Management
Hong Kong
– -$142M -771,618 Closed
Neuberger Berman Group
71
Neuberger Berman Group
New York
– -$141M -769,228 Closed
T. Rowe Price Associates
72
T. Rowe Price Associates
Maryland
– -$133M -725,032 Closed
SGCM
73
Sand Grove Capital Management
United Kingdom
– -$132M -717,127 Closed
N
74
Nuveen
North Carolina
– -$131M -715,115 Closed
CC
75
Carlson Capital
Texas
– -$125M -679,150 Closed
1 2
3
4 5

ALXN Hedge Fund Activity: Q3 2021 in Review

7 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2021, worth a combined $845K — down 100% from $38.8B a quarter earlier.

Sellers outnumbered buyers: 693 funds closed out of ALXN and 1 opened new positions — a net loss of 692 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Neo Ivy Capital Management, opening a new position worth an estimated $475K. The largest seller was Vanguard Group, exiting entirely with an estimated $3.74B sold.

  • 7 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2021, down from 707 in Q2 2021.
  • Funds reported $845K of Alexion Pharmaceuticals stock for Q3 2021, down 100% quarter-over-quarter.
  • 1 fund opened new Alexion Pharmaceuticals positions in Q3 2021 and 693 closed out, a net change of -692 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2021 was Neo Ivy Capital Management, an estimated $475K added.
  • The largest Alexion Pharmaceuticals seller in Q3 2021 was Vanguard Group, an estimated $3.74B sold.

Based on aggregated 13F filings for Q3 2021.